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Abstract
Photobiomodulation, otherwise known as low-level laser (or light) therapy, is an
emerging modality for the management of hair loss. Several randomized trials have
demonstrated that it is safe and potentially effective on its own or in combination
with standard therapies. These devices come in many forms including wearable caps
or helmets that afford hands-free and discreet use. Models with light-emitting diodes
(LEDs) are less expensive compared to laser-based devices and do not require laser
safety considerations, thus facilitating ease of home use. Limitations include cost of
the unit, risk of information bias, and lack of standardized protocols. Finally, as with
any hair loss treatment, patients' expectations with regards to therapeutic outcomes
must be managed.
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1 | I NTRO D U C TI O N

mice using a ruby laser.4 In 2007, the HairMax LaserComb (Lexington
International) became the first LLLT device to be granted clearance

It is estimated that about 50% of men and women will experience
1

by the United States Food and Drug Administration (US FDA) for the

some form of hair loss over the course of a lifetime. Although hair

treatment of pattern hair loss in men and was expanded to include

loss in itself does not directly result in any functional impairment, its

women in 2011. As of September 2020, there are 66 LLLT devices

impact on an individual's outward appearance can cause significant

registered with the US FDA.5

psychological issues including anxiety, depression, social phobia,
1

Low-level laser (or light) therapy devices are generally catego-

post-traumatic stress disorder, and suicidality. Regardless of the

rized into: (a) stationary hoods, (b) hand-held combs or brushes, (c)

type of alopecia, the prospect of a long-term and even permanent

headbands, and (d) caps or helmets.6 Stationary hood designs are

hair loss is especially distressing to patients, prompting them to seek

common in office-based LLLT devices like the Capillus272 Office

treatment aggressively. Many options, both prescription and over-

Pro (Curallux)7 and the Sunetics Clinical Laser (Sunetics International

the-counter, are available and have been used to treat different

Marketing Group).8 Combs and brushes are capable of parting the

types of hair loss albeit with varying success.

hairs on the scalp thus facilitating better penetration of light to the

An emerging treatment for hair loss is photobiomodulation

hair follicle; however, they require manual movement by the patient

(PBM), which is also known as low-level laser (or light) therapy (LLLT).

especially for those with extensive scalp involvement. In contrast,

The terms PBM and LLLT will be used interchangeably throughout

hat-based systems such as caps or helmets have the advantage of

this article. PBM was first introduced during the 1960s and has been

being “hands-free”.9 Caps in particular offer the added benefit of dis-

used for a variety of indications including wound healing, nerve re-

creet use. An example is the Capillus Laser Therapy Cap (Curallux),

generation, pain reduction, body contouring, and even tinnitus. 2,3 Its

which received FDA clearance in 2015.5 Following its commercial

potential for hair restoration was first discovered in 1967 by Endre

success, the potential role of LLLT in the management of other types

Mester after inadvertently inducing hair regrowth in experimental

of hair loss such as alopecia areata (AA) and scarring alopecias have

© 2021 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd
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been explored, although no device has been approved by the US
FDA for these indications. This review focuses on clinical studies involving home LLLT devices that employ a hat-based system and their
efficacy on different types of alopecia.

2 | BA S I C CO N C E P T S I N
PH OTO B I O M O D U L ATI O N
Photobiomodulation involves the use of light within the visible

TA B L E 1
(LED)

Differences between laser and light-emitting diode

Laser

LED

Coherent

Incoherent

Collimated

Divergent

Very narrow bandwidth (<1 nm)

Wider
bandwidth
(1-2 nm)

Higher cost per mW

Lower cost per
mW

red (600-700 nm) or near infrared (NIR) (700 nm-1400 m) range10
that is produced from a laser or light-emitting diode (LED) source.
These wavelengths coincide with the “optical window” of mamma-

LEDs are less expensive and do not require the cautionary measures

lian skin, that is, the wavelength at which there is maximal absorp-

that must be observed with lasers, which facilitates ease of home

tion of light.11 Unlike regular lasers which produce tissue heating or

use.16 The key differences between laser and LED are summarized

ablation, absorption of light by a chromophore in PBM produces a

in Table 1. Currently, many commercially available PBM devices have

photochemical effect that is analogous to photosynthesis in plants.11

light sources that consist of LED only (Revian Red, PhotonMD Inc.), 21

Cytochrome C oxidase, a member of the mitochondrial electron

or a combination of laser and LED (Tables 2 and 3).

transport chain, acts as the chromophore that leads to production
of adenosine triphosphate (ATP), generation of reactive oxygen species, and induction of cell signaling. This results in cell proliferation,
down-regulation of inflammation, increased tissue oxygenation,
wound healing, nerve regeneration, and pain reduction.12 Recently,
PBM has been found to enhance the expression of signaling mol-

3 | PH OTO B I O M O D U L ATI O N A S H A I R
LOS S TR E ATM E NT
3.1 | Androgenetic alopecia

ecules of the Wnt/B-catenin pathway, which is involved in the initiation of growth and development of hair follicles.13

Androgenetic alopecia (AGA) is the most common type of hair loss

A key concept in PBM is the precise modulation of the dose

in both men and women. It affects 80% of Caucasian men and up

delivered whereby too low of a dose would be inadequate to pro-

to 42% of Caucasian women by the age of 70, 22 hence, it has been

duce a response, while too high would cause an inhibitory effect.11

regarded by some as a normal part of the aging process. The char-

This concept has been demonstrated in several dose-response

acteristic pathology is a progressive miniaturization of the hair fol-

studies.14,15 It is also thought to be responsible for the paradoxical

licle that leads to formation of thin, short (vellus) hair. Currently,

hair growth that is sometimes seen in laser hair removal, as well

the only treatments approved by the United States Food and Drug

as the failure of LLLT to produce hair growth in some trials.11 For

Administration (US FDA) for AGA are topical minoxidil solution and

2

purposes of hair growth, a dose of 4 J/cm at wavelengths between
2

630 and 660 nm, irradiance of 5 mW/cm and treatment duration
6

oral finasteride, 23 while oral dutasteride is approved in South Korea
and Japan. 24 Other options include oral bicalutamide, 25 oral spirono-

of 10-20 minutes is typically employed. The total dose delivered

lactone, intralesional injections with platelet rich plasma (PRP), and

to the scalp and the time required to deliver the desired dose are

hair transplant. 23

determined by the number of laser diode or LED units built into the

Several randomized controlled studies have demonstrated that

device, such that a greater number of units will have higher power

PBM for AGA is safe and effective either alone or in combination

density or irradiance, and therefore require less time to deliver a

with prevailing therapies. One of the earliest studies investigated

desired dose.6

the hair growth promoting capability of a 655 nm laser hand-

As mentioned, the light generated in LLLT may either come from

held LLLT device with a comb attachment (HairMax LaserComb;

a laser or LED source. Until the early 2000s, LLLT devices reported in

Lexington International) in men with AGA. Results showed that

literature consisted of purely lasers, either from a helium-neon (He-

patients who used the HairMax LaserComb for 15 minutes thrice

Ne) lamp or laser diode. It was believed that the beneficial effects of

weekly for 26 weeks had increased terminal hair density from base-

PBM were due to the laser's innate properties, namely coherence,

line, while those who received a sham device noted a decrease in

monochromaticity, or collimation. However, one review argued that

terminal hair density. No serious adverse effects were reported. 26 It

since PBM is meant to elicit a photochemical rather than a thermal

was this study that eventually paved the way for FDA clearance of

or ablative effect, it is not necessary for the light source to be co-

the HairMax LaserComb. 27

16

herent.

Several in vitro, animal, and human studies comparing pho-

The 650 nm Capillus Laser Therapy Cap (Curallux), then

tobiomodulation using laser versus LED (an incoherent light source)

known as the Handi-Dome Laser device, was debuted in a trial by

revealed that the two are equally effective in terms of wound heal-

Friedman et al In this study, 44 women with AGA were random-

ing, reducing inflammation, and relieving pain.17-20 Furthermore,

ized to undergo home treatment with either the laser cap or a

650 nm laser diode (272
units)

660 ± 10 nm laser diode
(224 units)

630 nm LED (24 units),
660 nm LEDs (18 units),
650 nm laser diode (27
units)

660 ± 5 nm LED (27 units),
650 ± 10 nm laser diode
(27 units)

620 nm and 660 nm LED
(119 units)

RAMACAP helmetd

Oaze helmete

iRestore ID-520 helmet f

Revian Red capg

655 nm laser (9 units)

Capillus Laser Therapy
Cap (CapillusPro)c

b

Specifications

Not specified

≤22 (LED), ≤4.6
(laser)

3.5 (630 nm),
2.5 (660 nm), 4
(650 nm)

3.5 (max: 5), Dose:
4 J/cm2

5

Not specified

Irradiancea (mW/
cm2)

Double-blind, sham
device-controlled,
multicenter RCT

Double-blind, halfhead, sham devicecontrolled, single
center RCT

Double-blind, sham
device-controlled,
multicenter RCT

Double-blind, sham
device-controlled,
single center RCT

81 (21 females,
60 males)

100 (17
females, 83
males)

40 (14 females,
26 males)

40 (20 females,
20 males)

44 females

42 (21 females,
11 males)

Retrospective
observational study

Double-blind, sham
device-controlled,
multicenter RCT

110 males

Subjects

Double-blind, sham
device-controlled,
multicenter RCT

Study design

Summary of PBM/LLLT devices evaluated for the treatment of androgenetic alopecia in human trials

HairMax LaserComb

Device

TA B L E 2

10 min daily for
26 wks

30 min, 3×/wk
for 24 wks

18 min, daily for
24 wks

20 min, 3×/wk
for 24 wks

30 min, every
other day for
17 wks

8-15 min, 3×/
wk, variable
duration
(2-24 mo)

15 min, 3×/wk
for 26 wks

Treatment
parameters

Average increase in target area hair
count by 26.3 per cm2 as early
as 16 wks among device-treated
group versus sham-treated group.

Significant increase in hair coverage
(14.2%) on LLLT-treated side versus
sham-treated side (11.8%) based
on gross photographic assessment;
Device-treated side showed
significant increase in hair count,
hair thickness and investigator's
global assessment versus shamtreated side

Device-treated group showed
significant increase in mean hair
density by 17.2 hairs/cm2 (versus
decrease by 2.1 hairs/cm2 in
sham-treated group) and mean
hair thickness by 12.6 µm (versus
3.9 µm in sham-treated group).

Device-treated group showed
significant increase in mean hair
density by 10.21 hairs/cm2 versus
3.95 hairs/cm2 in sham-treated
group) and mean hair diameter by
6.11 µm (versus 3.76 µm in shamtreated group).

Significant increase in terminal hair
counts by 51% compared to shamtreated patients.

Significant improvement in 25%
(8/32), moderate improvement in
63% (20/32), and no improvement
in 12% (4/32) based on global
photographic assessment.

Significant increase in mean terminal
hair density by 19.8 hairs/cm2
in device-treated group versus
decrease by 7.6 hairs/cm2 in shamtreated group.

Results

|
(Continues)

32

30

29

9

28

34

26
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655 nm laser diode (21
units), 650-670 nm LED (30
units)

Specifications
<5

Irradiancea (mW/
cm2)
Single-blind, single
center, three-arm
RCT

Study design
45 females

Subjects
25 min, 3×/wk
for 4 mo

Treatment
parameters

h

Apira Science, Boca Raton, Florida.

PhotonMD Inc., Morrisville, North Carolina.

WELLMIKE Technology Corporation, New Taipei City, Taiwan.

g

f

Won Technology, Daejeon, Korea.

e

Ramathibodi Hospital Division of Dermatology and National Innovation Agency, Thailand.

Curallux, Miami, Florida.

d

c

Lexington International, Boca Raton, Florida.

Per unit of laser or LED.

b

a

Abbreviations: F, female; LLLT, low-level light (or laser) therapy; M, male; PBM, photobiomodulation; RCT, randomized controlled trial.

h

(Continued)

iGrow helmet

Device

TA B L E 2

Downgrading of Ludwig
classification in all patients, but
greatest in LLLT + minoxidil; LLLT
monotherapy patients showed
significant increase in hair density
from baseline, but no significant
difference when compared to
LLLT + minoxidil and minoxidil
alone.

Results
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660 nm laser diode (204
units)

650 nm LED (105 units)

Capillus Laser Therapy
Cap (Capellux 19)c

Tricoglam helmetd
5

25.5

5

1.8

Case series

Case series

Case series

Single-arm study

2 females (60- and
65-year-old)

28-year-old, female

42-year-old, female

15 (9 females, 6 males)

5 min/d or 20 min, 2×/
wk for 6 mo

7 min daily for 12 mo

6 min daily for 18 mo

4-s pulses every 1 s
for 3 min, every 1 or
2 wks, variable duration
(average: 1.8 mo)

Treatment parameters

Per unit of laser or LED.

Jeffrey Paul's Hair & Scalp Specialists, Fairview Park, Ohio.

Curallux, Miami, Florida.

d

c

Tokyo Iken, Tokyo, Japan.

b

a

Abbreviations: F, female; LLLT, low-level light (or laser) therapy; M, male; PBM, photobiomodulation; RCT, randomized controlled trial.

650 nm laser diode (272
units)

600-1600 nm polarized
linear light with probe
(in-office procedure)

Capillus Laser Therapy
Cap (CapillusPro)c

Lichen planopilaris

Super Lizerb

Alopecia areata

Subjects

Device

Study design

Irradiancea
(mW/cm2)

Specifications

Summary of PBM/LLLT devices evaluated for the treatment of other types of hair loss in human trials

TA B L E 3

Reduction peripilar casts
on dermoscopy and
improvement of symptoms
(itching)

Reduction peripilar casts
on dermoscopy and
improvement of symptoms
(itching)

Reduction peripilar casts
on dermoscopy and
improvement of symptoms
(itching)

Hair regrowth in more than
50% of involved areas in 7
out 15 patients

Results

42

42

42

40

Reference
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sham device for 30 minutes every other day for 17 weeks. Results

3.2 | Alopecia areata

showed that participants who received the active device had 51%
more terminal hair count from baseline compared to controls and

Alopecia areata (AA) is an autoimmune, inflammatory, non-scarring

no adverse reactions or side effects were reported. 28 Similarly, a

hair loss disorder with a lifetime incidence of 1.7%-2.1%. It can occur

study done in Thailand revealed that men and women who used a

at any age, but is most prevalent among children and young adults.36

660 nm helmet-type laser device for 24 weeks exhibited greater

The characteristic histologic finding is a peribulbar infiltration of

mean hair density and diameter by almost 3-fold, and 2-fold, re-

T-lymphocytes resembling a “swarm of bees.”37 A variety of thera-

spectively, compared to placebo. Two laser-treated participants

peutic agents including topical, intralesional, and systemic treat-

reported pruritus that resolved spontaneously and did not war-

ments have been used in AA, but none have been proven to sustain

rant discontinuation of therapy.

9

remission.38

A helmet-type device (Oaze; Won Technology) consisting of

Unlike AGA, there is limited data regarding PBM for AA. A 2012

630 nm LEDs, 660 nm LEDs, and 650 nm laser diodes was utilized

animal study revealed that the HairMax LaserComb successfully

in a study by Kim et al In this trial, participants who underwent LLLT

elicited hair growth in a C3H/HeJ mouse model for AA with histo-

for 18 minutes daily for 24 weeks exhibited greater hair density and

logic evidence of increased anagen hair follicles. This was in contrast

hair thickness from baseline compared to placebo (sham device). 29

to sham-treated mice which demonstrated no response and showed

In addition, a 24-week half-head comparison of a laser-LED helmet

telogen follicles with absent hair shafts on histology.39 Meanwhile,

device (650 nm laser diode with 660 nm LED) versus placebo re-

one study which utilized an infrared light instrument (Super Lizer;

vealed significantly greater increases in hair coverage, hair count,

Tokyo Iken) successfully elicited hair regrowth in 7 out of 15 pa-

and hair thickness from baseline on the treated side as compared

tients in an average of 1.8 months of 1-2× weekly use. There were

to the non-treated side which showed a decrease in these param-

no adverse reactions except for a sensation of heat reported by one

eters. Eczema, pruritus, and acneiform eruption were the reported

patient.40

side effects.

30

The mechanism through which PBM induces hair growth in

In 2018, an all-LED, dual wavelength (620 nm and 660 nm) LLLT

AA is thought to be anti-inflammatory. Activation of the electron

cap device known as the Revian Red (PhotonMD Inc.) received

transport chain shifts the macrophage activated in AA from a pro-in-

FDA clearance for the treatment of AGA in men and women. 31 Its

flammatory M1 to an anti-inflammatory M2 phenotype, thereby re-

efficacy and safety were evaluated in a prospective, randomized

ducing the inflammation that otherwise attacks the hair follicle and

controlled, double-blind study involving 81 subjects who were

causes hair loss.6

asked to use the device for 10 minutes daily. Results showed that
after 16 weeks, patients who were treated with Revian Red had
an average increase in target area hair count by 26.3 per cm. 2 The

3.3 | Lichen planopilaris

most common treatment-related adverse effects were pruritus,
dandruff, and rash. 32

Lichen planopilaris (LPP) is a scarring type of hair loss that tends to

Photobiomodulation has been found to work synergistically with

be more frequent among adult females.41 In general, scarring alope-

approved therapies for AGA. One study involving 45 women com-

cias differ from non-scarring alopecias in that inflammation results

pared LLLT with a laser-LED helmet device (iGrow, Apira Science)

in destruction of the hair follicle that leads to permanent loss of hair

versus minoxidil 5% solution versus a combination of the two. After

growing capability. As such, the goal of therapy is to retard the pro-

4 months, all treatment groups exhibited downgrading of Ludwig

gression of hair loss by reducing inflammation.42

classification for female pattern hair loss, with greatest improvement

In a case series of four females aged 28-65 with lichen plano-

seen among those who utilized combination therapy.33 Similarly,

pilaris, the use of a 650 nm laser cap device for 5-7 minutes daily

a study conducted by Munck et al34 compared the combination of

as an adjuvant to medical therapy resulted in decreased clinical and

HairMax LaserComb with topical minoxidil or oral finasteride versus

dermoscopic signs of active disease, namely scalp erythema, pruri-

HairMax LaserComb alone and found that LLLT on its own is poten-

tus, hair shedding, and peripilar casts at 3 months. There was also

tially effective but works better when co-administered with medical

evident regrowth of hair and no adverse reactions were reported.

therapy.

Of note, no comparison with medical therapy alone was presented.

The exact mechanism as to how PBM induces hair growth in AGA
is still poorly understood but is postulated to be due to increased

Reduction of inflammation is the likely mechanism of PBM in these
cases.42

proliferation of matrix cells in the hair follicle as a result of the activation of the cellular respiratory chain. 26,35 Additionally, the irradiation
causes an increase in blood circulation at the dermal papilla, which
10,26

provides a boost of metabolic activity to the proliferating cells.

4 | LI M ITATI O N S O F
PH OTO B I O M O D U L ATI O N

PBM has also been hypothesized to drive telogen follicles into anagen phase and prolong its duration, resulting in production of longer

Photobiomodulation has several limitations. Among them, the

and thicker (terminal) hair. 23

most evident is the cost of the unit. The price of the PBM devices

|
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mentioned in this review range from US $200 (HairMax LaserComb)
to US $3000 (Capillus Laser Therapy Cap).

43-45

LEDs cost signifi-

cantly lower than lasers. One review noted that the cost per mW

7
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some models may be an effort to lower costs.
While majority of the LLLT devices available in the market are
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fice-based treatment may be suitable for patients who wish to have a
trial of PBM prior to purchasing their own device.46 However, in-of-
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5 | CO N C LU S I O N
Photobiomodulation or LLLT is a safe and potentially effective modality for the management of hair loss. It can be conveniently administered from home, and certain models offer hands-free, discreet
use.
Among the devices reviewed above, the Capillus Laser Therapy
Cap stands out in terms of design (sports cap style), treatment time
(6-7 minute sessions daily), and available data (tested on different
types of hair loss). However, further large-scale studies on the different LLLT devices are needed in order to corroborate efficacy
data, establish an optimal treatment protocol, and determine the
ideal patient candidate. Based on currently available data, PBM may
be recommended as an alternative for failed standard therapy or as
an adjunct to prevailing treatments. The cost of PBM devices is a
limitation, although combined laser-LED devices are less expensive
options. Lastly, management of patients' expectations is an essential
part of patient education.
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